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ABSTRACT
Background: Despite recent progress, pneumonia
remains the largest infectious killer of children globally.
This paper describes outcomes of not treating
community-diagnosed fast-breathing pneumonia on
patient recovery.
Methods: We conducted an exploratory subanalysis of
an observational prospective cohort study in Malawi.
We recruited children (2–59 months) diagnosed by
community health workers with fast-breathing
pneumonia using WHO integrated community case
management (iCCM) guidelines. Children were followed
at days 5 and 14 with a clinical assessment of
recovery. We conducted bivariate and multivariable
logistic regression for the association between
treatment of fast-breathing pneumonia and recovery,
adjusting for potential confounders.
Results: We followed up 847 children, of whom 78
(9%) had not been given antibiotics (non-treatment).
Non-treatment cases had higher baseline rates of
diarrhoea, non-severe hypoxaemia and fever. Non-
recovery (persistence or worsening of symptoms) was
13% and 23% at day 5 in those who did receive and
those who did not receive co-trimoxazole. Non-
recovery, when defined as worsening of symptoms
only, at day 5 was 7% in treatment and 10% in
non-treatment cases. For both definitions, combined
co-trimoxazole and lumefantrine-artemether (LA)
treatment trended towards protection (adjusted OR
(aOR) 0.28; 95% CI 0.12 to 0.68/aOR 0.29; 95% CI
0.08 to 1.01).
Conclusion: We found that children who did not
receive co-trimoxazole treatment had worse clinical
outcomes; malaria co-diagnosis and treatment also
play a significant role in non-recovery. Further research
into non-treatment of fast-breathing pneumonia, using
a pragmatic approach with consideration for malaria
co-diagnosis and HIV status is needed to guide
refinement of community treatment algorithms in this
region.
BACKGROUND
Pneumonia is estimated to kill 0.9 million
children each year, with the highest burden
in Africa.1 2 Reductions in pneumonia mor-
tality have been seen over the last decade for
signiﬁcant bacterial causes of child morbidity
and mortality, with widespread introductions
of vaccines for Haemophilus inﬂuenzae type B
and Streptococcus pneumoniae.3 4 Increased
access to these effective vaccines elevates the
importance of understanding the role of
non-bacterial illnesses that cause fast breath-
ing, such as viral respiratory infections and
non-respiratory illnesses like malaria, so that
children with increased respiratory rates
receive appropriate care.
The integrated community case manage-
ment (iCCM) guidelines recommended by
the WHO stratify pneumonia severity and
subsequent treatment according to clinical
symptoms.5 Non-severe cases (age-adjusted
fast breathing without chest indrawing or
danger signs) are currently recommended
Strengths and limitations of this study
▪ This is an exploratory subanalysis of a prospect-
ive observational study, with data on concurrent
diagnoses, treatments and outcomes collected in
a rural routine care setting.
▪ Oral antibiotics and lumefantrine-artemether
treatment were not randomised, and therefore
the study is subject to bias, although we
adjusted for confounders and clustering in the
analysis.
▪ Pneumonia diagnosis and recovery was based
on the WHO integrated community case manage-
ment guidelines, enhanced with pulse oximetry.
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for treatment at home with oral antibiotics; however,
antibiotics may not be necessary. American and
European guidelines do not recommend antibiotics for
bronchiolitis, a lower respiratory infection that can
present with fast breathing and therefore mimic WHO
iCCM pneumonia.6 In sub-Saharan African settings, mul-
tiple studies have reported the overlap of malaria and
pneumonia diagnoses, resulting in overtreatment for
both conditions.7–9
Treatment failure—the persistence of symptoms or clin-
ical deterioration following antibiotic initiation—10can
have many causes, including incorrect initial diagnosis
(eg, malaria and not pneumonia), host comorbidities
(eg, malnutrition), poor antibiotic adherence, and viral
or antibiotic-resistant causative organisms.11 Published
treatment failure rates for fast-breathing pneumonia
range from 7% to 21%.12–15 Recent evidence from
South Asia suggests that treating fast-breathing pneumo-
nia with a placebo has equivalent recovery rates to the
recommended course of oral antibiotics, reporting a
treatment failure (or non-recovery) rate of 8% with or
without antibiotics.14
Research is needed into the non-treatment of
fast-breathing pneumonia in an African setting, where
HIV and malnutrition (key risks for poor outcomes16 17)
rates are high, and access to care may be more limited.
In Malawi community health workers (CHWs) dispense
oral antibiotics in the community based on clinical
assessments, and in this setting non-treatment refers to
the lack of antibiotic dispensing by the CHW, not a care
givers refusal of treatment. We aimed to take advantage
of prospective observational data to describe outcomes
for children diagnosed with fast-breathing pneumonia at
the community level in Malawi who did not receive an
antibiotic compared with those who received
co-trimoxazole.
METHODS
This analysis is based on data collected as part of a pro-
spective cohort study to predict treatment failure in chil-
dren treated with oral co-trimoxazole for fast-breathing
pneumonia in Malawi. Full methods of data collection
and management have previously been published.15
Data were collected from September 2013 to June 2014
in subpopulations of two districts in the central region
of Malawi (Mchinji and Lilongwe districts). The popula-
tion catchments were rural and made up of predomin-
antly subsistence farmers, covering ∼50 000 people, of
which 17% were estimated to be children under the age
of 5 years.18
Data collection
Brieﬂy, patients were recruited from community-level
primary care clinics (village clinics) run by government
employed CHWs called Health Surveillance Assistants.
Information from the initial clinical assessment (includ-
ing pulse oximetry with Lifebox) and diagnosis was
recorded on case report forms by the CHW, along with
their referral or treatment decision. For each CHW,
local village-level data collectors (VDCs) conducted
follow-up interviews in recruited patients’ homes at days
5 and 14, with the day of diagnosis being day 0. VDCs
attended village clinics to recruit patients and at
follow-up visits conducted a clinical assessment of the
child (including pulse oximetry), asked about additional
care seeking and antibiotic adherence. Children identi-
ﬁed as ‘not recovered’ at follow-up were referred by the
VDC back to the CHW for further assessment and if
needed, referral or treatment. We conducted data quality
assurance exercises, including a vital signs standardisation
audit conducted by a paediatric pulmonologist (EDM)
and random Global Positioning System (GPS) spot
checks by ﬁeld supervisors of follow-up locations.
Definitions
The cohort was deﬁned as all children aged 2–59 months
with CHW-diagnosed WHO fast-breathing pneumonia.
Fast-breathing pneumonia was deﬁned according to the
2013 WHO iCCM guidelines,19 as the presence of cough
and/or difﬁculty breathing and fast breathing (>50 bpm
for infants 2–11 months; >40 bpm for children 12–59
months), in the absence of any danger signs or chest
indrawing. Danger signs were recorded based on care-
giver’s report and clinical observation, and included
vomiting everything, unable to feed, convulsions in the
previous 24 hours, sleepy or unconscious, and signs of
severe respiratory distress including grunting, severe hyp-
oxaemia (peripheral oxygen saturation (SpO2) <90%),
nasal ﬂaring and head nodding. Wheeze was not specif-
ically assessed or recorded. All children who were
severely malnourished (mid-upper arm circumference
(MUAC) <11.5 cm) were also referred. We deﬁned mod-
erate malnutrition as a MUAC between 11.5 and
13.5 cm, well nourished as >13.5 cm, and non-severe
hypoxaemia as a SpO2 of 90–94%. Malaria diagnosis was
based on clinical presentation and presumptive treat-
ment of fever, without the use of rapid diagnostic tests
or laboratory conﬁrmation, as this was standard care at
the time of this study. HIV testing was not offered by par-
ticipating CHWs as this service also was not standard
care.
Children were deﬁned as ‘complete treatment’ or
‘non-treatment’ cases. Complete treatment cases were those
who received and completed >80% of the 5-day, twice
daily course of co-trimoxazole (where one dose is: 1/2
tablet for 2–11 months; 1 tablet for 12–59 months),
according to standard guidelines in Malawi at the time
of the study. Non-treatment cases were those who did not
receive antibiotics from the CHW at their diagnosis or
from any other source, according to caregiver’s report
and VDC inspection. Non-adherent cases were those who
received antibiotics but completed <80% of the recom-
mended doses. There were 80 cases (9%) that were non-
adherent and we excluded these cases from the analysis
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to focus on non-treatment rather than incomplete or
partial treatment effects.
Non-recovery deﬁnitions are presented in box 1. We used
two deﬁnitions for non-recovery at day 5: (1) the persist-
ence or worsening of symptoms, including fast breathing
for age (deﬁnition 1—persistence and/or progression);
(2) the worsening of symptoms, without considering fast
breathing for age (deﬁnition 2—progression). A change
in antibiotic was based on caregiver’s report, with a
named antibiotic prescribed by any level of clinical staff,
and where possible visually veriﬁed by the VDC. At day
14, relapse (patients who had previously recovered) and
non-recovery (classiﬁed as not recovered on day 5) were
deﬁned using the same parameters.
Analysis
All analyses were carried out using Stata SE13. We
described the non-treatment and treatment cases. We
conducted bivariate and multivariable analysis of out-
comes at day 5 (using both deﬁnitions of non-recovery)
for treatment and non-treatment cases; we did not do
this for day 14 outcomes due to the small number of
relapse/non-recovery cases. We considered the following
variables in the multivariable analysis: clinical malaria
diagnosis and lumefantrine-artemether (LA) treatment;
other clinical diagnoses and treatments; initial clinical
presentation including—temperature, SpO2, respiratory
rate and malnutrition; age; and gender. These variables
were included based on previously published associa-
tions with treatment failure,15 and differences observed
between treatment and non-treatment groups to adjust
for potential confounding. We imputed missing data
values for those patients who completed follow-up at day
5, using chained equations with 10 rounds of imput-
ation.20 A total of 226 records had an imputed value
(24%); a sensitivity analysis of complete case analysis is
available in online supplementary ﬁle 1. Robust SEs
were used to account for clustering with the Stata
command -vce(robust)-, and intracluster correlation coefﬁ-
cients reported. A bivariate analysis, stratiﬁed by pres-
ence of fever at CHW diagnosis is presented in online
supplementary ﬁle 2.
Ethics
Informed verbal consent for follow-up and clinical
assessment was sought from the accompanying caregiver.
Results
A total of 1542 cases were assessed for eligibility. Of
these, 487 (32%) were not eligible (eg, too old or
without fast breathing), 197 (17%) were lost to follow-up
due to respondent unavailability, VDC unavailability or
unknown (ﬁgure 1). Overall 938 cases were followed at
day 5, with 847 cases retained for analysis, and of these
754 (89%) were also followed at day 14. Of these fol-
lowed cases 78 (9%) were non-treatment cases.
Table 1 summarises baseline demographic and clinical
signs of treatment and non-treatment cases. Treatment
cases were similar to non-treatment cases in terms of
demographics, but the cases that did not receive antibio-
tics had higher baseline reports of diarrhoea, additional
treatments given and higher rates of non-severe hypox-
aemia and fever. Figure 2 presents the proportion of
non-treatment cases by CHW. Non-treatment cases were
seen in 16 of the 38 CHW clusters and there was consid-
erable variation in the number of children recruited and
which received treatment between the CHWs. The
intracluster correlation coefﬁcients for non-recovery
were 0.146 (95% CI 0.058 to 0.234) and 0.082 (95% CI
0.022 to 0.142) based on deﬁnitions 1 and 2, respectively.
The rate of non-recovery (persistence and/or progres-
sion—deﬁnition 1) for non-co-trimoxazole treatment
Box 1 Non-recovery definitions
▸ Non-recovery definition 1 (persistence and/or progression)—
presence of any of the following on day 5 of follow-up: fast
breathing for age or parameters from non-recovery definition 2.
▸ Non-recovery definition 2 (progression)—presence of any of
the following on day 5 of follow-up: axillary temperature
>37.5°C, lower chest indrawing, any danger sign (as defined
in the Methods section), change of antibiotic, hospital admis-
sion or death.
▸ Relapse/non-recovery—presence of any of the following on
day 14 of follow-up in children cured on day 5 (relapse) or
not-recovered on day 5 (non-recovery): fast breathing for age
or parameters from non-recovery definition 2.
Figure 1 Case recruitment.
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cases was 23% and for treatment cases was 13%.
Children treated with both co-trimoxazole and LA had a
non-recovery rate of 12% (unadjusted OR 0.32; 95% CI
0.15 to 0.70). Considering progression only (deﬁnition
2), non-recovery was 7% and 10% in those who did and
did not receive antibiotics, respectively; non-recovery
decreased to 5% in children with combined
co-trimoxazole and LA treatment (unadjusted OR
0.44; 95% CI 0.14 to 1.36). Unadjusted results, including
relapse/non-recovery at day 14 are presented in table 2.
Notably, we did not register any deaths during the
2-week follow-up period.
Results of the bivariate and multivariate analysis are
presented in table 3. For both deﬁnitions of non-
recovery at day 5, having either clinically diagnosed
malaria or any other diagnosis was associated with
increased odds of a poor outcome. For deﬁnition 1,
being older and having non-severe hypoxaemia also
showed an increased risk for non-recovery. The com-
plete case analysis demonstrated similar results to the
imputed model, with the exception of co-trimoxazole
only treatment for progression to more severe illness
(deﬁnition 2), which trended towards recovery (adjusted
OR (aOR) 2.02; 95% CI 0.29 to 14.01). However, the
wide CIs demonstrate the uncertainty and lack of power
in the complete case analysis (see online supplementary
ﬁle 1).
Of the patients with malaria diagnosis 81% received
LA, while 36% of those who received LA had no
malaria diagnosis documented (correlation 0.49)—this
incorrect treatment with LA was higher in non-
treatment cases (40% vs 31%), as was correct treatment
for concurrent malaria diagnosis (84% vs 81%). The
association of co-trimoxazole and LA treatment on
recovery for both deﬁnitions demonstrated protective
effects; for deﬁnition 1 (persistence/progression) com-
bined treatment showed a 72% decrease in non-
recovery (aOR 0.28; 95% CI 0.12 to 0.68). In deﬁnition
2 (progression), the effect size was similar for combined
treatment (aOR 0.29; 95% CI 0.08 to 1.01) although
decreased power led to wider CIs.
DISCUSSION
This paper describes non-recovery in children diagnosed
with fast-breathing pneumonia in the community in
rural Malawi, speciﬁcally looking at the impact of
co-trimoxazole and LA treatment. Our results suggest
that oral co-trimoxazole treatment may be beneﬁcial at
the community level for children with fast-breathing
pneumonia as part of routinely delivered community-
based care. We found concurrent diagnoses, including
malaria, to be important factors in non-recovery, as well
as poorer guideline adherence by CHWs when treating
children with possible baseline comorbidities, highlight-
ing CHW inconsistencies when implementing iCCM
guidelines. The role of malaria and treatment with both
co-trimoxazole and LA in this setting needs further
research and understanding to reﬁne clinical diagnosis
and treatment guidelines.
Interestingly, we found that the children who did not
receive co-trimoxazole treatment had more comorbid-
ities at baseline (more non-severe hypoxaemia, diar-
rhoea and fever), and received more alternative
treatments such as salbutamol tablets, aspirin and skin
creams. These baseline differences could explain the
CHW decision to not administer oral antibiotics, if the
CHW suspected them of having an alternative diagnosis
Table 1 Description of demographics and clinical
presentation in treatment and non-treatment cases
Treatment
(%)
N=769
Non-treatment
(%)
N=78
Variable
District
Mchinji 350 (46%) 33 (42%)
Lilongwe 419 (54%) 45 (58%)
Age (months)
2–11 238 (31%) 21 (27%)
12–23 252 (33%) 25 (32%)
24–59 279 (36%) 32 (41%)
Gender
Girl 395 (51%) 33 (42%)
Boy 359 (47%) 43 (55%)
Missing 15 (2%) 2 (3%)
Other treatments and diagnoses
Clinical malaria diagnosis 309 (40%) 25 (32%)
Diarrhoea diagnosis 22 (3%) 8 (10%)
Other diagnosis* 63 (8%) 5 (6%)
LA treatment given 386 (50%) 42 (54%)
Paracetamol given 383 (50%) 48 (61%)
Other treatment given** 15 (2%) 8 (10%)
Clinical features
Mean (SD)
N (%)
Mean (SD)
N (%)
MUAC (cm) 14.7 (1.4) 15.0 (1.6)
Moderate malnutrition 108 (14%) 9 (12%)
Missing 149 (19%) 17 (22%)
Temperature (°C) 37.1 (1.0) 37.4 (1.0)
Fever 252 (33%) 35 (45%)
Missing 34 (4%) 9 (12%)
Respiratory rate (bpm)
2–11 months 55.5 (5.4) 56.0 (5.8)
12–59 months 47.6 (7.2) 49.3 (5.8)
Very fast 40 (5%) 3 (4%)
Missing 40 (5%) 3 (4%)
Oxygen saturation (SpO2%) 96.4 (1.9) 96.2 (2.7)
Non-severe hypoxaemia 117 (15%) 21 (27%)
Missing 11 (1%) –
Very fast breathing: >70 bpm in 2–11 months old and >60 bpm in
12–59 months old. Moderate malnutrition: MUAC 11.5–13.5 cm.
Non-severe hypoxaemia: SpO290–94%.
*Other diagnoses includes: ear infection (n=2), rash (n=2) or other
unspecified (n=64).
**Other treatments include salbutamol (n=5), aspirin (n=9) and
any creams (n=9).
LA, lumefantrine-artemether; MUAC, mid-upper arm
circumference; SpO2, oxygen saturation.
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to pneumonia (ie, malaria and/or diarrhoea with dehy-
dration), despite meeting WHO iCCM criteria—reﬂect-
ing the lack of speciﬁcity of fast breathing for
pneumonia. Skin creams were likely dispensed to treat
rashes, which could be due to a variety of causes such as
self-limiting (eg, a viral exanthema) or higher risk infec-
tions (eg, Staphylococcus aureus), especially if the child is
malnourished or HIV affected. While not recommended
as part of iCCM care and not common in our study
(n=5), a CHW may attempt to treat ‘noisy’ breathing in
the community with salbutamol tablets. A child can have
‘noisy’ breathing due to many causes including a benign
self-limiting viral upper respiratory tract infection, or dis-
eases like bronchiolitis or croup that may lead to slower
recovery, or non-recovery, as was observed in both deﬁni-
tions. None of these conditions would necessarily
improve with salbutamol treatment, and all could result
in a secondary bacterial infection that would beneﬁt
from a course of antibiotics. Alternatively the CHW may
have diagnosed them with more severe illness and
recommended them for referral, with this being misun-
derstood by the caregiver or not carried out, resulting in
non-treatment and poor recovery.
This study has highlighted the variation in both
numbers of reported pneumonia cases and treatment
between different CHWs. We did not capture informa-
tion on reasons for non-treatment; however, changes in
funding for essential drug procurement in Malawi were
occurring during the time of this study, and it is possible
that this resulted in localised drug stock-outs and there-
fore non-treatment. Alternatively non-treatment and low
case ascertainment may reﬂect poor quality of care and
implementation of treatment guidelines by CHWs. The
recent introduction of an mHealth drug stock system
(cStock) into Malawi aims to address the issue of stock-
outs, although an initial baseline survey found that 27%
Figure 2 Distribution of case
recruitment and non-treatment by
community health worker.
Table 2 Association of treatment with co-trimoxazole and LA with non-recovery at days 5 and 14
Day 5
N=116/847
Day 14
N=65/754
n/N (%) OR 95% CI n/N (%) OR 95% CI
Definition 1
No co-trimoxazole 18/78 (13%) 1.00 12/70 (8%) 1.00
Co-trimoxazole 98/769 (23%) 0.49 0.28 to 0.86 53 684 (17%) 0.41 0.21 to 0.80
No treatment 11/36 (31%) 1.00 9/31 (29%) 1.00
LA only 7/42 (17%) 0.45 0.15 to 1.34 3/39 (8%) 0.20 0.05 to 0.83
Co-trimoxazole only 50/383 (13%) 0.34 0.16 to 0.74 23/341 (7%) 0.18 0.07 to 0.43
Co-trimoxazole+LA 48/386 (12%) 0.32 0.15 to 0.70 30/343 (9%) 0.23 0.10 to 0.55
N=59/847 N=33/754
Definition 2
No co-trimoxazole 8/78 (10%) 1.00 10/70 (15%) 1.00
Co-trimoxazole 51/769 (7%) 0.62 0.28 to 1.36 23/684 (4%) 0.21 0.10 to 0.47
No treatment 4/36 (11%) 1.00 7/31 (24%) 1.00
LA only 4/42 (10%) 0.84 0.19 to 3.64 3/39 (8%) 0.26 0.06 to 1.12
Co-trimoxazole only 31/383 (8%) 0.70 0.23 to 2.12 8/341 (2%) 0.08 0.03 to 0.24
Co-trimoxazole+LA 20/386 (5%) 0.44 0.14 to 1.36 15/343 (5%) 0.15 0.06 to 0.41
LA, lumefantrine-artemether.
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of CHWs did not have all essential drugs available.21
Even with systems such as cStock, close supervision and
quality control in the use of CHWs for treatment of
childhood illnesses is necessary to ensure consistent and
accurate implementation of standardised treatment
guidelines.
The multivariate analysis, for both deﬁnitions of non-
recovery, demonstrated the association of empiric
malaria co-diagnosis with non-recovery, and this was par-
ticularly pronounced when using progression of clinical
symptoms as the deﬁnition of non-recovery. This associ-
ation remained even once treatment with both
co-trimoxazole and LA were considered—potentially a
reﬂection of the poor correlation between the diagnosis
and treatment, with almost 20% of malaria cases not
receiving LA treatment. These relationships suggests that
non-recovery at day 5 is being driven by either
co-infection with malaria or initial misdiagnosis (and
therefore mistreatment) of malaria as pneumonia.
Co-trimoxazole has been shown to prevent malaria infec-
tions as part of prophylaxis treatment for HIV patients
and to be an effective malaria treatment.22 Considering
evidence from prior studies demonstrating considerable
overlap between malaria and pneumonia, as deﬁned by
WHO clinical deﬁnitions7–9 co-trimoxazole may be treat-
ing both bacterial pneumonia and malaria infections in
this population. Despite our ﬁndings suggesting that
combined co-trimoxazole and LA treatment may be
beneﬁcial in children meeting the WHO iCCM
fast-breathing pneumonia deﬁnition our data support
Table 3 Bivariate and multivariable analysis following multiple imputation of non-recovery at day 5
Unadjusted Adjusted*
Variable OR 95% CI p Value OR 95% CI p Value
Treatment failure definition 1 (persistence and/or progression)
No treatment 1.00 1.00
LA only 0.45 0.15 to 1.34 0.152 0.59 0.18 to 1.98 0.397
Co-trimoxazole only 0.34 0.16 to 0.74 0.006 0.57 0.25 to 1.32 0.187
Co-trimoxazole+LA 0.32 0.15 to 0.70 0.004 0.28 0.12 to 0.68 0.005
Clinical malaria diagnosis 1.58 1.07 to 2.35 0.022 2.21 1.30 to 3.75 0.003
Other diagnosis** 1.85 1.08 to 3.17 0.025 1.89 1.08 to 3.28 0.025
Other treatment*** 1.51 1.01 to 2.26 0.042 1.63 0.99 to 2.68 0.052
Gender (male) 1.29 0.87 to 1.92 0.206 1.36 0.90 to 2.06 0.149
Age (months)
2–11 1.00 1.00
12–23 2.32 1.34 to 4.00 0.003 2.60 1.45 to 4.65 0.001
24–59 2.07 1.20 to 3.56 0.009 2.40 1.34 to 4.27 0.003
Moderate malnutrition 1.51 0.89 to 2.55 0.123 1.44 0.85 to 2.45 0.172
Fever 0.67 0.42 to 1.05 0.079 0.63 0.39 to 1.02 0.058
Very fast breathing 0.86 0.33 to 2.23 0.756 0.69 0.24 to 2.01 0.500
Non-severe hypoxaemia 1.92 1.20 to 3.06 0.006 1.75 1.05 to 2.93 0.032
Treatment failure definition 2 (progression)
No treatment 1.00 1.00
LA only 0.84 0.19 to 3.64 0.818 0.66 0.13 to 3.43 0.617
Co-trimoxazole only 0.70 0.23 to 2.12 0.534 0.89 0.27 to 2.90 0.840
Co-trimoxazole+LA 0.44 0.14 to 1.36 0.152 0.29 0.08 to 1.01 0.052
Clinical malaria diagnosis 1.77 1.04 to 3.01 0.035 3.24 1.59 to 6.60 0.001
Other diagnosis** 1.95 0.97 to 3.89 0.060 2.21 1.10 to 4.43 0.025
Other treatment*** 1.01 0.59 to 1.71 0.984 1.23 0.62 to 2.42 0.552
Gender (male) 1.68 0.97 to 2.90 0.062 1.77 0.99 to 3.17 0.054
Age (months)
2–11 1.00 1.00
12–23 0.50 0.23 to 1.11 0.088 0.55 0.24 to 1.26 0.155
24–59 1.48 0.81 to 2.72 0.203 1.68 0.87 to 3.22 0.120
Moderate malnutrition 1.78 0.89 to 3.55 0.101 1.32 0.63 to 2.75 0.457
Fever 0.69 0.36 to 1.30 0.248 0.76 0.38 to 1.50 0.427
Very fast breathing 0.70 0.16 to 2.98 0.631 0.79 0.17 to 3.63 0.763
Non-severe hypoxaemia 1.38 0.71 to 2.69 0.340 1.39 0.69 to 2.77 0.358
Fever: temperature ≥37.5°C; mild hypoxaemia: oxygen saturation 90–94%.95%; moderate malnutrition: MUAC 11.5–13.5 cm; very fast
breathing; >70 bpm in 2–11 months and >60 bpm in 12–59 months.
*The adjusted model included all the variables from the bivariate analysis.
**Other diagnoses include ear infection, rash or other unspecified.
***Other treatments include salbutamol, aspirin and any creams.
LA, lumefantrine-artemether.
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the need for more reﬁned treatment algorithms in
malaria endemic regions.
The main limitation of this study was that it was not
randomised. As a subanalysis of an observational cohort
designed to investigate predictors of treatment failure,
all children should have received oral co-trimoxazole
for home treatment of fast-breathing pneumonia,
according to iCCM guidelines. However, considering
this was a quasi-programmatic setting, breaches in
guideline implementation were seen among some of
the CHW—demonstrating considerable inter-CHW vari-
ation. This analysis takes advantage of these failures to
describe outcomes in non-treatment cases; however, this
may reduce the generalisability of the results to other
settings. We see that children were not randomly allo-
cated to receive or not receive antibiotics (the same
being true for LA treatment), therefore our analysis is
subject to selection bias at the CHW level. Owing to
the lack of blinding (both of the care giver and CHW)
the apparent beneﬁt among treated children could, in
part, reﬂect a placebo effect for some caregiver-
reported symptoms if they were pleased to have
received treatment, especially if supplies were scarce.
Similarly, as the CHWs were not blinded to treatment,
their assessment of respiratory rate and other signs and
symptoms may have been biased; and this could have
been confounded by socioeconomic factors or knowl-
edge of comorbidities such as HIV status. We had a
17% loss to follow-up which may lead to biases in the
analysis. However, we have previously published that
were only minimal differences seen in nutrition and
PCV13 vaccination status between those lost and fol-
lowed up, therefore it is unclear if this would have
affected the results.15
We suggest that these results be cautiously interpreted
as preliminary data and not conclusive on the impact of
non-treatment of fast-breathing pneumonia in a high
HIV, malaria endemic setting. As this was a secondary
analysis without an a priori sample size, we are aware
that our study lacked power to test equivalency; however,
we still found a relationship between treatment and
outcome. Further research, such as a carefully moni-
tored randomised equivalency study, is needed in the
sub-Saharan African setting which accounts for HIV
status and laboratory-conﬁrmed malaria co-diagnosis to
build on this exploratory analysis. However, caution is
needed not to use a study design method which is com-
pletely explanatory. As rural CHW settings may not see
point-of-care diagnostic tools for malaria and HIV
(let alone universal coverage), a study design which
removes all of this ‘noise’ may lead to a false-positive
ﬁnding of equivalence, while in the reality of suboptimal
diagnosis and referral, antibiotics could still be beneﬁ-
cial. A balance between pragmatic and explanatory may
be more appropriate, an approach which has been high-
lighted in the revised PRECIS-2 tool23—a validated
research tool for delivering trials that are ﬁt for purpose.
In addition, an investigation into the use of placebos in
a programmatic setting in South Asia is needed, to
conﬁrm the ﬁndings from the trial setting in practice.
Our results suggest that non-treatment of children
meeting the current WHO iCCM deﬁnition for
fast-breathing pneumonia would not be advisable in a
rural sub-Saharan African setting with malaria endem-
icity. Malaria co-diagnosis and treatment play a signiﬁ-
cant role in non-recovery and so any trial in which
placebos are given in a similar setting would need to be
implemented under close clinical supervision to avoid
adverse outcomes, as well as tease out the complex rela-
tionships between antibiotics and LA with recovery.
However, we did not record any deaths and only two
children who did not receive an antibiotic sought add-
itional care within our 2 weeks of follow-up.
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